果蝇zeste基因增强子同源物2在乳腺癌组织中的表达及其与乳腺癌分子分型的相关性  

The relationship between expression of enhancer of zeste homolog 2 in breast cancer and molecular subtypes

作　　者：李杰宝[1] 喻晓程 田野[1] 张家衡[1] 

机构地区：[1]武汉市第一医院甲乳外科,430022

出　　处：《中华实验外科杂志》2016年第9期2196-2199,共4页Chinese Journal of Experimental Surgery

基　　金：2015年武汉市卫计委临床医学课题项目（WX15817）

摘　　要：目的 检测果蝇zeste基因增强子同源物2（EZH2）、细胞核增殖抗原（Ki-67）在乳腺癌组织中的表达,探讨EZH2的表达与新型乳腺癌分子分型及预后的相关性.方法 免疫组织化学方法检测42例临床乳腺癌组织石蜡切片中EZH2和Ki-67的表达水平,同时结合乳腺癌的病理检查结果雌激素受体（ER）、孕激素受体（PR）、人类表皮生长因子受体-2（Her-2）,按照新型乳腺癌分子分型标准,将乳腺癌进行分型;使用χ^2检验分析比较EZH2与乳腺癌临床病理参数及与乳腺癌新型分子分型间的关系;采用Kaplan-Meier法分析EZH2的表达与乳腺癌患者无病生存率的关系.结果 乳腺癌患者的年龄、肿瘤大小、绝经状态、淋巴结转移、术后分期等临床病理参数在乳腺癌分子分型间的差异无统计学意义（P＞0.05）,EZH2表达与乳腺癌患者的肿瘤大小、淋巴结转移、术后分期、ER、PR表达等临床病理参数明显相关（P＜0.05）.30例非三阴性型乳腺癌患者中占EZH2高表达为11例,低表达为19例;三阴性乳腺癌占12例,其中高表达10例,低表达2例,EZH2在三阴性乳腺癌中的表达明显高于非三阴性乳腺癌,差异有统计学意义（χ^2=7.467,P＜0.05）.且EZH2的表达在4组乳腺癌分子亚型间的差异也有统计学意义（χ^2 =9.24,P ＜0.05）.在随访超过5年的42例乳腺癌患者中,EZH2高表达的患者有6例死亡,2例复发、转移;EZH2低表达的患者有2例死亡,1例复发、转移.EZH2高表达组与EZH2低表达组的乳腺癌患者的无病生存率（DFS）差异有统计学意义（P＜0.05）.结论 EZH2在三阴性型乳腺癌高表达,它可成为三阴性型乳腺癌的分子标志物之一。Objective Expression of enhancer of zeste homolog 2 （EZH2） and proliferation cell nuclear antigen （Ki-67） in breast cancer tissue is tested,and the correlation between expression of EZH2,new molecular subtypes and prognosis of breast cancer are analyzed.The above may contribute to the adoption of new molecular markers and therapeutic target for the diagnosis,prognosis and therapy of breast cancer.Methods The expression level of EZH2 and Ki-67 in paraffin specimens of 42 breast cancer tissues were tested through immunohistochemistry method,while breast cancer is classified into several molecular subtypes,as for the expression of estrogen receptor （ER） and progesterone receptor （PR）,human epidermal growth factor receptor-2 （Her-2） in the results of pathological examination of breast cancer,according to the new standard of molecular subtypes of hreast cancer.The correlation between EZH2 and clinic pathological parameter and that between EZH2 and new molecular subtypes of breast cancer were analyzed and compared through Chi-square test.The correlation between expression of EZH2 and disease free survival of breast cancer patients was also analyzed through Kaplan-Meier method.Results No statistical significance existed in the differences of molecular subtypes of breast cancer as for the age of patient,size of tumor,menopausal status,lymph node metastasis,postoperative pathological stages and other clinical pathological parameters（P 〉 0.05）.The expression of EZH2 was correlated with the size of tumor,lymph node metastasis,postoperative pathological stages,expression of ER and PR （P 〈 0.05）.There were 30 triple negative breast cancer patients,including higher expression of EZH2 in 11 cases and lower expression in 19.Twelve patients who were other types of breast cancer were observed,including 10 cases higher and 2 cases lower expression of EZH2.The expression of EZH2 in triple negative breast cancer was higher than that in the other types of breast cancer,while there was significant differ

关 键 词：乳腺癌 分子分型 免疫组织化学 果蝇zeste基因增强子同源物2 

分 类 号：R737.9[医药卫生—肿瘤]